Your Health, We Care
Crizotinib is indicated for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) whose tumors are anaplastic lymphoma kinase (ALK) or ROS1-positive as detected by an FDA-approved test.
Crizotinib is indicated for the treatment of pediatric patients 1 year of age and older and young adults with relapsed or refractory, systemic anaplastic large cell lymphoma (ALCL) that is ALK-positive. Limitations of Use: The safety and efficacy of Crizotinib have not been established in older adults with relapsed or refractory, systemic ALK-positive ALCL.
Crizotinib is indicated for the treatment of adult and pediatric patients 1 year of age and older with unresectable, recurrent, or refractory inflammatory myofibroblastic tumor (IMT) that is ALK-positive.
from FDA，2023.09
Understanding the appropriate population and strategy of the drug can provide pa···【more】
Release date：2025-03-31Recommended：59
Crizotinib provides an innovative treatment pathway for patients to address the ···【more】
Release date：2025-03-31Recommended：60
Innovations in targeted therapies have led to breakthrough treatment options for···【more】
Release date：2025-03-28Recommended：72
